Senores Pharmaceuticals Limited (BOM:544319)
India · Delayed Price · Currency is INR 1,042.95
-5.85 (-0.56%)
At close: Jun 4, 2026
Senores Pharmaceuticals Revenue
In the fiscal year ending March 31, 2026, Senores Pharmaceuticals had annual revenue of 6.33B INR with 58.85% growth. Senores Pharmaceuticals had revenue of 1.75B in the quarter ending March 31, 2026, with 53.39% growth.
Revenue
6.33B
Revenue Growth
+58.85%
P/S Ratio
7.53
Revenue / Employee
n/a
Employees
194
Market Cap
47.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 6.33B | 2.34B | 58.85% |
| Mar 31, 2025 | 3.98B | 1.84B | 85.65% |
| Mar 31, 2024 | 2.15B | 1.79B | 507.07% |
| Mar 31, 2023 | 353.37M | 211.67M | 149.38% |
| Mar 31, 2022 | 141.70M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Unichem Laboratories | 22.65B |
| FDC Limited | 21.71B |
| Morepen Laboratories | 18.06B |
| Sanofi India | 17.74B |
| Hikal | 17.13B |
| Procter & Gamble Health | 14.08B |
| CORONA Remedies | 14.03B |
| Gufic Biosciences | 9.47B |